[go: up one dir, main page]

SI1587584T1 - Farmacevtska kombinacija za profilakso ali terapijo kardiovaskularnih, kardiopulmonalnih, pulmonalnih ali renalnih bolezni - Google Patents

Farmacevtska kombinacija za profilakso ali terapijo kardiovaskularnih, kardiopulmonalnih, pulmonalnih ali renalnih bolezni

Info

Publication number
SI1587584T1
SI1587584T1 SI200430377T SI200430377T SI1587584T1 SI 1587584 T1 SI1587584 T1 SI 1587584T1 SI 200430377 T SI200430377 T SI 200430377T SI 200430377 T SI200430377 T SI 200430377T SI 1587584 T1 SI1587584 T1 SI 1587584T1
Authority
SI
Slovenia
Prior art keywords
cardiopulmonary
prophylaxis
pulmonary
cardiovascular
therapy
Prior art date
Application number
SI200430377T
Other languages
English (en)
Inventor
Axel Riedel
Jose-Maria Sendra
Josef M E Leiter
Stefan Kauschke
Michael Mark
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10301372A external-priority patent/DE10301372A1/de
Priority claimed from DE10335027A external-priority patent/DE10335027A1/de
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Int
Publication of SI1587584T1 publication Critical patent/SI1587584T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200430377T 2003-01-16 2004-01-14 Farmacevtska kombinacija za profilakso ali terapijo kardiovaskularnih, kardiopulmonalnih, pulmonalnih ali renalnih bolezni SI1587584T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10301372A DE10301372A1 (de) 2003-01-16 2003-01-16 Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
DE10335027A DE10335027A1 (de) 2003-07-31 2003-07-31 Verwendung von Angiotensin II Rezeptor Antagonisten
EP04701918A EP1587584B1 (de) 2003-01-16 2004-01-14 Pharmazeutische kombination zur prophylaxe oder therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen krankheiten
PCT/EP2004/000175 WO2004062729A1 (de) 2003-01-16 2004-01-14 Pharmazeutische kombination zur prophylaxe oder therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen krankheiten

Publications (1)

Publication Number Publication Date
SI1587584T1 true SI1587584T1 (sl) 2007-10-31

Family

ID=32714792

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200430377T SI1587584T1 (sl) 2003-01-16 2004-01-14 Farmacevtska kombinacija za profilakso ali terapijo kardiovaskularnih, kardiopulmonalnih, pulmonalnih ali renalnih bolezni

Country Status (22)

Country Link
US (2) US20050004193A1 (sl)
EP (2) EP1587584B1 (sl)
JP (1) JP2006515877A (sl)
KR (1) KR20050092119A (sl)
AT (1) ATE362782T1 (sl)
AU (1) AU2004204353A1 (sl)
BR (1) BRPI0406812A (sl)
CA (1) CA2513281C (sl)
CY (1) CY1106775T1 (sl)
DE (1) DE502004003880D1 (sl)
DK (1) DK1587584T3 (sl)
EA (1) EA009886B1 (sl)
EC (1) ECSP055914A (sl)
ES (1) ES2287689T3 (sl)
HR (1) HRP20050655A2 (sl)
MX (1) MXPA05007559A (sl)
NO (1) NO20053793L (sl)
PL (1) PL376213A1 (sl)
PT (1) PT1587584E (sl)
RS (1) RS20050536A (sl)
SI (1) SI1587584T1 (sl)
WO (1) WO2004062729A1 (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
EP1814527B2 (en) * 2004-11-05 2020-11-18 Boehringer Ingelheim International GmbH Bilayer tablet comprising telmisartan and amlodipine
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
US20090030057A1 (en) * 2005-11-22 2009-01-29 Shlomit Wizel Pharmaceutical composition of telmisartan
DK2089047T3 (da) * 2006-12-11 2013-02-18 3D Matrix Inc Sammensætninger og fremgangsmåder til beskyttelse og regenerering af hjerte-væv
EP2281557A4 (en) 2008-04-29 2011-08-31 Hanall Biopharma Co Ltd PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT
WO2010075347A2 (en) * 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
HRP20170263T2 (hr) * 2011-12-09 2018-12-28 Ims Medical D.O.O. LIJEČENJE ARTERIJSKE STJENKE KOMBINACIJOM RAAS INHIBITORA I HMG-CoA REDUKTAZE
WO2013136277A1 (en) * 2012-03-13 2013-09-19 Unimark Remedies Ltd. Pharmaceutical compositions for treatment of cardiovascular diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2577233C (en) * 1996-04-05 2009-08-18 Takeda Pharmaceutical Company Limited Pharmaceutical composition containing angiotensin ii antagonist
US20010006656A1 (en) * 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
EE05670B1 (et) * 1999-08-30 2013-08-15 Aventis Pharma Deutschland Gmbh Ramipriil kardiovaskulaarsete haigusjuhtude „rahoidmiseks
SK14642002A3 (sk) * 2000-04-12 2003-05-02 Novartis Ag Kombinované farmaceutické prostriedky obsahujúce antagonistu AT1-receptora a/alebo inhibítor HMG-CoA reduktázy a/alebo ACE inhibítor
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
JP4585198B2 (ja) * 2002-12-27 2010-11-24 武田薬品工業株式会社 体重増加抑制剤

Also Published As

Publication number Publication date
EA009886B1 (ru) 2008-04-28
KR20050092119A (ko) 2005-09-20
EA200501057A1 (ru) 2006-02-24
CA2513281C (en) 2012-04-03
MXPA05007559A (es) 2005-09-21
WO2004062729A8 (de) 2004-10-07
AU2004204353A1 (en) 2004-07-29
DK1587584T3 (da) 2007-09-24
EP1587584B1 (de) 2007-05-23
PT1587584E (pt) 2007-06-11
CA2513281A1 (en) 2004-07-29
BRPI0406812A (pt) 2005-12-27
US20050004193A1 (en) 2005-01-06
CY1106775T1 (el) 2012-05-23
WO2004062729A1 (de) 2004-07-29
NO20053793L (no) 2005-08-10
EP1818056A1 (de) 2007-08-15
PL376213A1 (en) 2005-12-27
EP1587584A1 (de) 2005-10-26
JP2006515877A (ja) 2006-06-08
ES2287689T3 (es) 2007-12-16
ECSP055914A (es) 2006-03-01
US20110190277A1 (en) 2011-08-04
RS20050536A (sr) 2007-09-21
HRP20050655A2 (en) 2006-05-31
DE502004003880D1 (de) 2007-07-05
ATE362782T1 (de) 2007-06-15

Similar Documents

Publication Publication Date Title
NO2024010I1 (no) Gefapixant, or a pharmaceutically acceptable salt thereof
NO2018029I1 (no) Alogliptin i kombinasjon med metformin, hver eventuelt i form av et farmasøytisk akseptabelt salt derav
LTC1562603I2 (lt) Nauji vaistai, skirti lėtinių obstrukcinių plaučių ligų gydymui
NO2017051I2 (no) Kariprazin, eventuelt i form av et salt
HUS1500034I1 (hu) Indolidon-származékok fibrózisos betegségek kezelésére vagy megelõzésére
NL1029015A1 (nl) Therapeutische verbindingen.
IS8516A (is) Fosfónöt, monofosfónamidöt, bisfosfónamidöt til meðhöndlunar á veirusjúkdómum
NO20070753L (no) Fremgangsmåte for fremstilling av dihydropteridinoner
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
DE602005024846D1 (de) Blutdialysator
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
DK1817282T3 (da) Til behandling af respiratoriske sygdomme egnede phenoxy derivater
IL176629A0 (en) Sulfonamide derivatives for the treatment of diseases
IS7755A (is) Aðferð við framleiðslu á (S,S)-cis-2-benshýdríl-3-bensýlamínókínuklídín
SI1587584T1 (sl) Farmacevtska kombinacija za profilakso ali terapijo kardiovaskularnih, kardiopulmonalnih, pulmonalnih ali renalnih bolezni
PL2422786T3 (pl) Nowe kombinacje środków leczniczych do leczenia chorób dróg oddechowych
DK1562954T3 (da) CCR1-antagonister til behandling af I.A. inflammatorisk demyelinisationssygdom
IS7163A (is) Aðferðir til meðhöndlunar á lungnasjúkdómi
DE602004022810D1 (de) Mehrdosis-inhalator
NL1024677A1 (nl) Therapeutische prolinederivaten.
SI1940409T1 (sl) Nove zdravilske kombinacije za zdravljenje bolezni dihalnih poti
SI3332789T1 (sl) Režim zdravljenja s kladaribinom za zdravljenje multiple skleroze
DE602005010492D1 (de) EKG-Referenzwertberechnung
EP1951337A4 (en) EXTRACORPORAL BLOOD CLEANSING
IS7537A (is) Notkun á nýjum etónógestrel esterum.